Imagine if we could grow the medicinal secrets of the ocean in a lab instead of diving for them. Instead of harvesting rare sponges or corals from the wild, this project creates 'cell factories' that multiply rapidly in bioreactors. It is like switching from hunting for wild berries to growing them in a high-tech greenhouse.
High-value marine compounds are currently limited by the inefficiency and environmental damage of wild harvesting. There is a critical bottleneck in stock production that prevents these compounds from being used in industrial-scale pharmaceuticals.
The project created the first continuous marine sponge cell line and developed 3D collagen scaffolds and photo-bioreactors to scale up production from 10mL to 125mL.
If you are a drug discovery firm dealing with the scarcity of rare marine metabolites—this project developed continuous marine sponge cell lines that provide a sustainable alternative to wild harvesting. This ensures a steady supply of high-value compounds for drug development.
If you are a skincare manufacturer dealing with unstable raw material sourcing from the ocean—this project developed 3D scaffolds made of marine collagen to scale up cell cultures. This allows for the consistent production of bioactive marine ingredients.
If you are a bioprocess company dealing with the difficulty of culturing marine organisms—this project developed a novel photo-bioreactor for corals with a day and night cycle. This technology enables the industrial-scale production of unique marine bio-based compounds.
Based on available project data, specific pricing or cost-per-unit information is not provided.
Yes, the project is designing a pathway for industrial bioprocessing and has already scaled cultures from 10mL flasks to 125mL custom bioreactors using 3D scaffolds.
Based on available project data, the specific licensing terms are not mentioned, though the project has achieved a breakthrough in creating the first continuous marine sponge cell line.
The project data notes that sponge cells from several species can divide extremely rapidly, though specific production timelines are not listed.
It replaces wild harvesting with a lab-grown bioprocess, solving the stock production bottleneck and contributing to a circular bioeconomy.
The consortium is research-heavy with 4 universities and 3 research institutes, but maintains a 22% industry ratio with 2 SMEs. This balance suggests a transition from fundamental discovery (like the first sponge cell line) toward commercial application, supported by partners across 8 countries.
Wageningen University
Contact us to explore licensing opportunities for marine cell line bioprocessing.
